Skip to main content
A 3rd Actemra biosimilar was approved by the FDA - Celltrion announced approval of its 7th biosimilar, Avtozma (CT-P47,

Dr. John Cush RheumNow

1 year 6 months ago
A 3rd Actemra biosimilar was approved by the FDA - Celltrion announced approval of its 7th biosimilar, Avtozma (CT-P47, tocilizumab-anoh); both IV & SCm for Rx of RA, GCA, pJIA, Still's dz & Covid-19. Joins other IL-6 biosimilars Tofidence (Biogen 10/23) & Tyenne (Frensius 3/24)… https://t.co/UtG9YOXUX2 https://t.co/j3LzG7beys
Congratulations to 2025 Crafoord Prize (in Polyarthritis) laureates Christopher Goodnow, (UNSW Sydney, Australia), and D

Dr. John Cush RheumNow

1 year 6 months ago
Congratulations to 2025 Crafoord Prize (in Polyarthritis) laureates Christopher Goodnow, (UNSW Sydney, Australia), and David Nemazee (Scripss,, USA) for their work on tolerance checkpoints - prevent B cells from attacking the body’s own tissues in autoimmune diseases… https://t.co/WSyXVIFJa1 https://t.co/JtBau2JSvo
BMC has published a full read literture review of pharmacological pain management in rheumatoid arthritis, pointing out that the best evidence for pain control comes from the use of DMARDs and treat-to-target strategies.  In contrast, there is widespread use of analgesics in RA, although the evidence supporting their use is often lacking.  More research in the area of pain management in RA is needed. 
The British Society for Rheumatology has published its guideline for the management of adult and juvenile onset Sjogren's disease. This guideline is an update to the 2017 guideline and is based on medical literature review focused on 19 clinical questions. While most of the diagnostic recommendations were "Strong", treatment recommendations were a mix of strong and "conditional" recommendation. 
QD Clinic - dsDNA without Lupus
Celecoxib Lowers Colon Cancer Recurrence Risk

The Alliance for Clinical Trials in Oncology today announced the results

Dr. John Cush RheumNow

1 year 6 months ago
Celecoxib Lowers Colon Cancer Recurrence Risk The Alliance for Clinical Trials in Oncology today announced the results of a data analysis from a randomized phase III clinical trial involving patients with stage III colon cancer, which found that adding the drug celecoxib to… https://t.co/tIoMtRlwKt https://t.co/fzOAplwJLi
JAMA has published a University of Minnesota cross-sectional study showing early adult (ages 25-44) mortality in the U.S. has risen substantially between 2011 to 2019 and 2020 to 2023. The largest portion of 2023 excess mortality was driven by drug poisoning, but many other external and natural causes exceeded what prior trends would have projected.
Full read review and overview of Fibromyalgia - manifestations, pathophysiology, treatments and guidelines. Multidiscip

Dr. John Cush RheumNow

1 year 6 months ago
Full read review and overview of Fibromyalgia - manifestations, pathophysiology, treatments and guidelines. Multidisciplinary, patient-centered treatment should includes a combination of pharmacological and nonpharmacological options. https://t.co/Go5T9pN6wH https://t.co/CIXai9OhZd
Blood Flow Restriction to Reduce Pain in Knee OA
  • MedPage Today
A technique now widely used in sports medicine to speed recovery from leg injuries helped reduce symptoms and improve function in people with osteoarthritis (OA) of the knee, a randomized trial showed.
UK NHS 2023-24 figures show hospitalization for SLE is 8X more common in blacks (62.6 per 100,000) compared to white SLE

Dr. John Cush RheumNow

1 year 6 months ago
UK NHS 2023-24 figures show hospitalization for SLE is 8X more common in blacks (62.6 per 100,000) compared to white SLE (7.8/100K) and Asian SLE (26/100K), Lupus hospitalizations risen 50% in 4 yrs (6,334 to 8,006 in 2023-24). Is this “stark” inequality from delayed Dx?… https://t.co/NDdIkWKZy5 https://t.co/E4Fmvz9uLn
RHEUMS! Please check out this important Survey on Cannibis/THS/CBD use in Rheumatology. This is a short survey (Ive d

Dr. John Cush RheumNow

1 year 6 months ago
RHEUMS! Please check out this important Survey on Cannibis/THS/CBD use in Rheumatology. This is a short survey (Ive done it) from the Rheumatology Research Foundation, FORWARD and the National Databank folks. We need to know more here; especially from you1 Link:… https://t.co/0KYbgqvceq https://t.co/JeO8hV0luB
FDA has approved Journavx (suzetrigine) 50 mg tablets, 1st in-class non-opioid analgesic, to treat moderate to severe ac

Dr. John Cush RheumNow

1 year 6 months ago
FDA has approved Journavx (suzetrigine) 50 mg tablets, 1st in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals… https://t.co/xKy7JY7pPr https://t.co/VYrDMQcjHc
Cross-sectional study of 50 SLE patients, 24% had fibromyalgianess, and 18% experienced widespread pain. Fibromyalgian

Dr. John Cush RheumNow

1 year 6 months ago
Cross-sectional study of 50 SLE patients, 24% had fibromyalgianess, and 18% experienced widespread pain. Fibromyalgianess in SLE patients primarily reflects heightened pain sensitivity and symptom severity rather than SLE disease activity. https://t.co/oLYc4IsIpN https://t.co/eHVIe9OXVF
Screening for #RA-Machine learning algorithm applied to primary healthcare pts shown to correctly identify early RA base

Dr. John Cush RheumNow

1 year 6 months ago
Screening for #RA-Machine learning algorithm applied to primary healthcare pts shown to correctly identify early RA based on 11 features (RF, CRP, ESR, SUA, HB, PLT, AMS, age, SJC TJC, deformity) w/ 96% specificity, 96% sensitivity, 96% AUC. https://t.co/Q25yvDwdJZ https://t.co/CTESAl6hSf
×